Literature DB >> 1242287

Prognosis of primary rhegmatogenous retinal detachments. 1. Associations between clinical detachment characteristics, subretinal fluid butyrylcholinesterase and visual outcome following scleral buckling procedures.

P L Kaufman.   

Abstract

Thirty-five patients with primary rhegmatogenous retinal detachments were followed for at least 6 months after scleral buckling procedures with subretinal fluid (SRF) drainage, in order to define factors influencing anatomic and visual outcome. Thirty-two cases were surgically reattached; three were not. Among the reattached cases, final visual acuity was poorer in patients with: older age; longer standing, more extensive detachments; detachment of the macula (with or without the development of a visible macular lesion); macular lesions; and higher SRF butyrylcholinesterase activity. These factors were themselves interrelated. Follow-up duration was only weakly related to final acuity, probably because of the long post-surgical follow-up. Phakic/aphakic status bore little relationship to final acuity. The type or timing relative to drainage of inflammation producing treatment was not related to final acuity.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1242287     DOI: 10.1111/j.1755-3768.1975.tb01785.x

Source DB:  PubMed          Journal:  Acta Ophthalmol (Copenh)        ISSN: 0001-639X


  4 in total

Review 1.  Deconstructing aqueous humor outflow - The last 50 years.

Authors:  Paul L Kaufman
Journal:  Exp Eye Res       Date:  2020-06-23       Impact factor: 3.467

2.  Delayed absorption of subretinal fluid after scleral buckling procedures: the significance of subretinal precipitates.

Authors:  D M Robertson
Journal:  Trans Am Ophthalmol Soc       Date:  1978

Review 3.  Recovery of visual acuity after retinal detachment involving the macula.

Authors:  T C Burton
Journal:  Trans Am Ophthalmol Soc       Date:  1982

4.  Binocular visual function after surgery for detached retina.

Authors:  T Amemiya; H Takami; H Yoshida; K Harayama
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1982       Impact factor: 3.117

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.